Congratulations:
Biocre Biotech, an enterprise settled in the park, has recently completed pre-A round of financing to raise a fund of tens of millions of yuan, and the investors were Tianjin Wanlian Daoyi Venture Capital and TSCapital.
In February 2022, Biocre received a Pre-A round of financing with a fund of 50 million yuan, with the investment led by Yuanbio Venture Capital, and followed by Shenzhen Angel Mother Fund, Guoke Jiahe and Xiamen Fengxue. The fund raised from this round of financing will mainly be used for biosynthesis of targeted bactericidal proteins and functional peptides and other products to accelerate the product deployment in such fields as effective skin health, pet intestinal health and rare metabolic diseases, and biological pesticides and plan to establish the first phase of industrial production base, as well as the team and talent introduction and the building of marketing team.
In September 2021, Biocre announced the completion of an angel round of financing to raise a fund of tens of millions of yuan, which was led by Shanghai Volcanics Capital and followed by Tianjin Haitang Fund and Shanghai Huixin Kangcheng Limited Partnership.
About Biocre
Founded in 2019, Biocre was located in the incubator of Industrial Biology Institute of Chinese Academy of Sciences in Tianjin Airport Economic Zone. In May 2021, its Shenzhen headquarters was settled in Shenzhen Industrial Innovation Center for Engineering Biology. It graduated from Innovation Center in July 2022, and officially moved to Heng Tai Yue Synthetic Biology Industrial Park on August 6. At present, it has research and development and pilot bases of 3,000 square meters in Shenzhen and Tianjin. It is worth mentioning that the company won the championship on the feasibility study track of the L-Oreal BIG BANG Global Beauty Technology Competition in 2021.
Biocre has established a complete chain synthetic biology platform around accurate protein design and protein molecular machine technology, focusing on efficient biosynthesis in such fields as skin health, pet intestinal health treatment, and biological pesticides. By using the intelligent automated high-flux screening system and efficient gene editing technology, it can modularize the development and production processes of biosynthesis and greatly improve the synthesis efficiency.
Zhang Jiaquan, co-founder and CEO of Biocre, said, the business models of synthetic biology enterprises were divided into platform type and product type, with typical companies of American synthetic biology giants Ginkgo and Amyris. The former, by building an integrated platform for biological design and software development, provides R&D and production services for customers in different industries such as food, medicine and chemicals. It does not complete the whole process of product production and sales and is not dependent on a single customer, though with a limited revenue in each single business. The latter has linked up the whole process of “R&D, design, testing, production and sales”, focusing on exploring the commercial value of products in a certain field, with a high ceiling of profits, but it depends on its ability to select products.
Focusing on problems such as skin health and rare metabolic diseases, Biocre has developed 7 product pipelines such as functional peptides and functional proteins, and promoted the research and development path of “route design, component design, strain construction, small test, pilot test, industrialization”, among which CRO project-acrylamide biosynthesis has achieved a large-scale industrial production of 40,000 tons.
In the application scenario of skin health, it has developed bacteriage bactericidal protein, and overcome problems such as eczema and acne caused by the imbalance of skin micro-ecology and biological preservation. It has cooperated with cosmetics enterprises like L’Oreal, and large-scale products are under the pilot test.
In the field of pet health, in order to effectively solve common intestinal problems such as pet enteritis and diarrhea, it has developed targeted proteins for harmful gastrointestinal colonies such as Salmonella and Escherichia coli. Compared with traditional antibiotic therapy, bactericidal proteins do not generate drug resistance, nor will destroy the beneficial bacteria in the pet’s gut, which can reduce the damage of antibiotics to pets and the environment.
The third part of the business comes from the field of biological pesticides. It has developed biodegradable biosurfactants to replace traditional chemical surfactants to improve the effect of pesticide administration and reduce the harm of traditional pesticides to the environment.
The founding team of the company is composed of biological scientists and doctors from top universities of Australia and experienced entrepreneurs. It has a profound accumulation in the interdisciplinary fields such as synthetic biology, protein engineering, artificial intelligence, bio-informatics computing and chemical engineering. By building platforms for precision protein design and protein molecular machine technology, and focusing on such fields as skin efficacy and skin care, rare metabolic diseases, pet intestinal health treatment, it has applied synthetic biology technologies such as gene editing to perform targeted treatment for harmful bacteria or harmful toxins that affect human health.